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T-cell-potentiating melanoma therapy
Metastatic melanoma patients face rising death rates and 
bleak survival estimates for distant metastases, and therapy 
involves enrollment in a clinical trial as the standard of care. 
Thus, Hodi and colleagues conducted a randomized double-
blind 676-patient phase III study to examine the efficacy of 
ipilimumab, a monoclonal antibody that blocks cytotoxic 
T-lymphocyte-associated antigen 4, in combination with a gly-
coprotein 100 (gp100) peptide vaccine and to compare the 
treatment with administration of gp100 alone. Treatment with 
ipilimumab both with and without gp100, as compared with 
gp100 alone, improved overall survival in metastatic melanoma 
patients who had undergone previous therapy, indicating that 
ipilimumab efficacy was not improved by gp100 administra-
tion. Reported adverse effects, most notably immune-related 
events such as diarrhea, may be treatment limiting. Taken 
together, these results indicate that ipilimumab may be useful as 
a treatment for metastatic melanoma patients who experienced 
disease progression following previous therapies. (N Engl J Med 
363:711–23, 2010) Selected by T. Schwarz
Risky adolescence
Studies of increased risk of melanoma following sunbed use 
have typically recruited people with melanoma diagnosed at 
any age. Thus, the specific associations between sunbed use 
and melanoma in young adults are not known. This relationship 
is particularly intriguing because younger people may have a 
greater susceptibility to the carcinogenic effects of artificial UV 
light. In an analysis of a population-based case–control family 
study of early-onset melanoma in Australia, Cust and colleagues 
demonstrated that sunbed use is a risk factor for early-onset 
(between ages 18 and 39) melanoma. Moreover, evidence of 
a dose–response relationship between the number of tanning 
bed sessions and melanoma risk was found in this population. 
The risk of melanoma was greater with earlier age of first sun-
bed use and for earlier onset disease. Because sunbed use was 
found to cause 76% of melanomas in 18- to 29-year-olds who 
have ever used a sunbed, efforts to restrict minors and discour-
age young adults from sunbed use should be intensified. (Int J 
Cancer, published online 28 July 2010; doi:10.1002/ijc25576, 
2010) Selected by M. Weinstock
Detrimental healing
Although Aqueous Cream BP is a widely used emollient for the 
treatment of dry skin and eczema, adverse cutaneous reactions 
occur frequently with use. These reactions may stem from the 
preservative chlorocresol, the antiseptic pheno xyethanol, or 
the anionic surfactant sodium lauryl sulfate (SLS). To examine 
the effects of this emollient on the skin barrier in vivo, Tsang 
and Guy examined the repeated, short-term application of 
this agent to forearm skin in six healthy female volunteers. 
Interestingly, this application led to a significant reduction in 
stratum corneum thickness and an overall increase in base-
line transepidermal water loss. Based on the composition of 
the emollient’s formulation, the authors concluded that SLS, 
an amphiphilic surfactant used for its solubilizing, suspension, 
and emulsifying properties, is the most likely culprit for these 
detrimental reactions. The observed results for healthy skin 
indicate that use of Aqueous Cream BP to treat eczema should 
be reconsidered because the barrier function of eczematous 
skin may already be compromised. (Br J Dermatol 163:954–8, 
2010) Selected by H. Williams
News on the forefront of psoriasis
Genome-wide association studies (GWAS) have implicated sev-
eral genomic regions (PSORS1, IL12B, IL23R, IL4-IL13, IL23A, 
TNIP1, TRNFIP3, LCE3B-LCE3C, DEFB4, and SPATA2-RNF114) 
in the pathogenesis of psoriasis; however, these genetic loci do 
not account for the observed variability in genetic susceptibil-
ity to this disease, indicating that other genetic factors remain 
unknown. Recently, three publications in Nature Genetics pre-
sented GWAS analyses that revealed new psoriasis susceptibility 
loci. Ellinghaus and colleagues performed genome-wide single-
nucleotide polymorphism analysis of 487 German psoriasis 
vulgaris cases and 1,161 controls. TRAF3IP2 on 6q21, which 
encodes the TRAF-interacting protein 2, was identified as a pso-
riasis-susceptibility locus. Stuart and colleagues similarly per-
formed a meta-analysis of recent GWAS that examined 4,064 
cases and 4,685 controls from the United States, Canada, and 
Germany. These analyses uncovered three new susceptibility 
loci at NOS2, which encodes inducible nitric oxide synthase: 
FBXL19, which encodes an inhibitor of NFκ light-chain enhancer 
of activated B cells (NF-κB); and PSMA6-NFKBIA, which encodes 
an inhibitor of NF-κB signaling and a subunit involved in major 
histocompatibility complex class I antigen processing, as well as 
confirming the recently reported association near RNF114.
Finally, Sun and colleagues extended their previous GWAS 
in the Chinese population and compared their results with 
studies from Germany and the United States. This study iden-
tified six new susceptibility loci associated with psoriasis 
and also confirmed one previously identified locus (TNIP1-
ANZA6). Several of the newly identified loci (ERAP1, PTTG1, 
CSMD1, GJB2, SERPINB8, and ZNF816A) have been impli-
cated in other autoimmune diseases. Interestingly, all six loci 
demonstrated significant heterogeneity between the Chinese 
samples and the European samples.
Taken together, these studies underscore the importance 
of the immune system in psoriasis and highlight new 
potential biological pathways involved in this chronic 
immune-mediated skin disease. (Nat Genet 42:991–5, 
2010; Nat Genet 42:1000–4, 2010; Nat Genet 42:1005–9, 
2010) Selected by T. Schwarz
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